Eccrine Porocarcinoma: A Review of the Literature

Eccrine porocarcinoma (EPC) constitutes a rare malignant adnexal tumor, which accounts for about 0.005–0.01% of all cutaneous malignancies. It may develop de novo or arise from an eccrine poroma, after a latency period of years or even decades. Accumulating data suggest that specific oncogenic drivers and signaling pathways may be implicated in its tumorigenesis, while recent data have demonstrated a high overall mutation rate attributed to UV exposure. Diagnosis may be challenging and should rely on the combination of clinical, dermoscopical, histopathological and immunohistochemical findings. The literature is controversial regarding tumor behavior and prognosis and, therefore, there is no consensus on its surgical management, utility of lymph-node biopsy and further adjuvant or systemic treatment. However, recent advances in tumorigenesis of EPC may aid in the development of novel treatment strategies, which could improve survival of advanced or metastatic disease, such as immunotherapy. This review presents an update of the epidemiology, pathogenesis and clinical presentation of EPC and summarizes current data on diagnostic evaluation and management of this rare cutaneous malignancy.

[1]  F. Tirode,et al.  Distinct regulations driving YAP1 expression loss in poroma, porocarcinoma and RB1‐deficient skin carcinoma , 2023, Histopathology.

[2]  C. Harwood,et al.  Variation in management of porocarcinoma: a 10-year retrospective review of 75 cases across three UK tertiary centres. , 2022, Clinical and experimental dermatology.

[3]  H. Ujiie,et al.  Diagnosis and Management of Porocarcinoma , 2022, Cancers.

[4]  C. Foti,et al.  PRAME Immunoexpression in 275 Cutaneous Melanocytic Lesions: A Double Institutional Experience , 2022, Diagnostics.

[5]  G. Lembarki,et al.  Eccrine porocarcinoma: an extremely rare cutaneous tumor from a radiological point of view – case report and review of the literature , 2022, BJR case reports.

[6]  H. Yeung,et al.  Incidence and trends of cutaneous adnexal tumors in the United States in 2000-2018: A population-based study. , 2022, Journal of the American Academy of Dermatology.

[7]  Athanasios Korogiannos,et al.  Dermatoscopic Features of a Metastatic Eccrine Porocarcinoma Arising on Lymphedema , 2022, Dermatology practical & conceptual.

[8]  D. Kalbermatten,et al.  Head and Neck Porocarcinoma: SEER Analysis of Epidemiology and Survival , 2022, Journal of clinical medicine.

[9]  V. Koljonen,et al.  UV-induced local immunosuppression in the tumour microenvironment of eccrine porocarcinoma and poroma , 2022, Scientific Reports.

[10]  A. Di Stefani,et al.  The role of postoperative radiotherapy in eccrine porocarcinoma: a multidisciplinary systematic review. , 2022, European review for medical and pharmacological sciences.

[11]  S. Vernon,et al.  Porocarcinoma: a review , 2022, Clinical and experimental dermatology.

[12]  M. Vinogradov,et al.  Metastatic Porocarcinoma Effectively Managed by Pembrolizumab , 2021, Cureus.

[13]  Jingxiang Huang,et al.  Unusual Presentations of Eccrine Porocarcinomas , 2021, Skin Appendage Disorders.

[14]  V. Koljonen,et al.  Merkel cell polyomavirus is a passenger virus in both poroma and porocarcinoma , 2021, Journal of cutaneous pathology.

[15]  S. Fröhling,et al.  High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma * , 2021, The British journal of dermatology.

[16]  B. Hutter,et al.  Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies , 2021, Cancer Gene Therapy.

[17]  G. Telang,et al.  Clear Cell Differentiation in Eccrine Porocarcinoma as a High-Risk Feature: Epidemiologic and Pathologic Features of Eccrine Porocarcinoma in a Single-Center Case Series , 2021, The American Journal of dermatopathology.

[18]  J. Swensen,et al.  Poroid adnexal skin tumors with YAP1 fusions exhibit similar histopathologic features: A series of six YAP1‐rearranged adnexal skin tumors , 2021, Journal of cutaneous pathology.

[19]  T. Sugino,et al.  Comparison of Immunohistochemical Expression of Cytokeratin 19, c-KIT, BerEP4, GATA3, and NUTM1 Between Porocarcinoma and Squamous Cell Carcinoma , 2021, The American Journal of dermatopathology.

[20]  V. Koljonen,et al.  Malignant Eccrine Porocarcinoma in Finland During 2007 to 2017 , 2020, Acta dermato-venereologica.

[21]  K. Patel,et al.  Surgical management and lymph-node biopsy of rare malignant cutaneous adnexal carcinomas: a population-based analysis of 7591 patients , 2020, Archives of Dermatological Research.

[22]  K. Moon,et al.  Eccrine Porocarcinoma: A Multicenter Retrospective Study with Review of the Literatures Reported in Korea , 2020, Annals of dermatology.

[23]  R. Seemann,et al.  Eccrine porocarcinoma of the head and neck: Meta‐analysis of 120 cases , 2020, Head & neck.

[24]  F. Samie,et al.  Demographics and outcomes of eccrine porocarcinoma: results from the National Cancer Database , 2020, The British journal of dermatology.

[25]  V. Bataille,et al.  Metastatic porocarcinoma achieving complete radiological and clinical response with pembrolizumab , 2019, BMJ Case Reports.

[26]  Rajiv M. Patel,et al.  Altered Rb, p16, and p53 expression is specific for porocarcinoma relative to poroma , 2019, Journal of cutaneous pathology.

[27]  K. Tsuta,et al.  Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. , 2019, The Journal of clinical investigation.

[28]  T. Sugai,et al.  Evaluation of Sentinel Lymph Node Biopsy for Eccrine Porocarcinoma. , 2019, Acta dermato-venereologica.

[29]  D. Greenberg,et al.  Eccrine Porocarcinoma of the Skin is Rising in Incidence in the East of England. , 2018, Acta dermato-venereologica.

[30]  A. Wysong,et al.  Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature , 2018, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[31]  C. Paul,et al.  Complete response of a metastatic porocarcinoma treated with paclitaxel, cetuximab and radiotherapy. , 2017, European journal of cancer.

[32]  P. Schirmacher,et al.  Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas. , 2017, Pathology.

[33]  F. Kakamad,et al.  Porocarcinoma; presentation and management, a meta-analysis of 453 cases , 2017, Annals of medicine and surgery.

[34]  P. Mendes-Bastos,et al.  Dermoscopic and reflectance confocal microscopic presentation of relapsing eccrine porocarcinoma. , 2017, Journal of the American Academy of Dermatology.

[35]  A. Weaver,et al.  Incidence and Clinical Features of Rare Cutaneous Malignancies in Olmsted County, Minnesota, 2000 to 2010 , 2017, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[36]  I. Nordman,et al.  Metastatic Eccrine Porocarcinoma: A Rare Case of Successful Treatment , 2016, Case Reports in Oncology.

[37]  M. Camilleri,et al.  Treatment of Porocarcinoma With Mohs Micrographic Surgery: The Mayo Clinic Experience , 2016, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[38]  S. Tomlins,et al.  Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations. , 2016, Human pathology.

[39]  K. Chanprapaph,et al.  Eccrine Poroma Arising within Nevus Sebaceous , 2016, Case Reports in Dermatology.

[40]  T. Hirose,et al.  CD117 (KIT) is a useful immunohistochemical marker for differentiating porocarcinoma from squamous cell carcinoma , 2016, Journal of cutaneous pathology.

[41]  E. Guevara-Gutiérrez,et al.  Eccrine porocarcinoma: epidemiologic and histopathologic characteristics , 2015, International journal of dermatology.

[42]  S. Aiba,et al.  Successful Treatment of Eccrine Porocarcinoma Metastasized to a Cervical Lymph Node with CyberKnife Radiosurgery , 2014, Case Reports in Dermatology.

[43]  L. Thomas,et al.  [Primary eccrine porocarcinoma: a clinicopathological study of 50 cases]. , 2014, Annales de dermatologie et de venereologie.

[44]  A. Maker,et al.  Survival after resection of cutaneous adnexal carcinomas with eccrine differentiation: Risk factors and trends in outcomes , 2013, Journal of surgical oncology.

[45]  J. A. van der Hage,et al.  Increasing incidence and survival of a rare skin cancer in the Netherlands. A population‐based study of 2,220 cases of skin adnexal carcinoma , 2013, Journal of surgical oncology.

[46]  A. Iafrate,et al.  Apocrine-Eccrine Carcinomas: Molecular and Immunohistochemical Analyses , 2012, PloS one.

[47]  T. Jouary,et al.  Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure , 2011, The British journal of dermatology.

[48]  S. Martinez,et al.  Rare tumors through the looking glass: an examination of malignant cutaneous adnexal tumors. , 2011, Archives of dermatology.

[49]  C. Cockerell,et al.  The New Seventh Edition American Joint Committee on Cancer Staging of Cutaneous Non-Melanoma Skin Cancer , 2011, American journal of clinical dermatology.

[50]  T. Mitsuishi,et al.  Pigmented poroid neoplasm mimicking nodular melanoma , 2010, The Journal of dermatology.

[51]  S. Devesa,et al.  Cutaneous appendageal carcinoma incidence and survival patterns in the United States: a population-based study. , 2010, Archives of dermatology.

[52]  T. Ruzicka,et al.  Eccrine Porocarcinoma of the Head: An Important Differential Diagnosis in the Elderly Patient , 2008, Dermatology.

[53]  H. Koga,et al.  Eccrine porocarcinoma: Clinical and pathological studies of 12 cases , 2007, The Journal of dermatology.

[54]  H. Kittler,et al.  Sentinel node status in melanoma patients is not predicitive for overall survival upon multivariate analysis , 2005, British Journal of Cancer.

[55]  B. Balda,et al.  Metastasising porocarcinoma following exposure to poison gas , 2002, The Lancet.

[56]  P. H. Mckee,et al.  Eccrine Porocarcinoma (Malignant Eccrine Poroma): A Clinicopathologic Study of 69 Cases , 2001, The American journal of surgical pathology.

[57]  C. Hees,et al.  Malignant eccrine poroma in a patient with Rothmiund‐Thomson syndrome , 1996, The British journal of dermatology.

[58]  Kunio Inoue,et al.  An immunohistologic study on eccrine gland carcinoma. , 1989, Journal of the American Academy of Dermatology.

[59]  D. Lowe,et al.  Malignant eccrine poroma: a study of twenty‐seven cases , 1982, The British journal of dermatology.

[60]  Y. Mishima,et al.  Oncogenic differentiation of the intraepidermal eccrine sweat duct: eccrine poroma, poroepithelioma and porocarcinoma. , 1969, Dermatologica.

[61]  H. Pinkus,et al.  EPIDERMOTROPIC ECCRINE CARCINOMA. A CASE COMBINING FEATURES OF ECCRINE POROMA AND PAGET'S DERMATOSIS. , 1963, Archives of dermatology.